Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 125 participants.

Also called NCT02764619

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02764619
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02764619. Randomized; quadruple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2017-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
Acronym
INSPIRE-AF
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
Svendborg Hospital (class: other)
Collaborator
Region of Southern Denmark (class: other)
Collaborator
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02764619
Content hash
7cfb5348aeb620471d8a1c3077e1482bcd3e6a84174b3115c7cdba94a88d9b47